Two years ago, I caved in to the pressure and signed up for a Twitter account. I had been resisting for months. Millions of people were flocking to the 140-character microblogging service, but from what I could see then, it looked like a time-wasting fad. Hardly anybody in the business I write about, biotechnology, was … Continue reading “Why Twitter Matters Now in Biotech, and Why Executives Can’t Ignore it Anymore”
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
MIT’s Bob Langer Strikes Again, Wins Priestley Medal
You know you’ve accomplished something in life when somebody gives you an award named after the guy who discovered oxygen. That was the position MIT bioengineering professor Bob Langer found himself in last week, when he took home another biggie—the Priestley Medal. This prize, the highest honor given by the American Chemical Society, usually doesn’t … Continue reading “MIT’s Bob Langer Strikes Again, Wins Priestley Medal”
Ambit Raises $30M Venture Round, After Pulling Plug on IPO
San Diego-based Ambit Biosciences wasn’t able to raise the kind of money it wanted from public market investors, so it has gone back to the VC world for another $30 million. Ambit said today it has put together a Series D-2 venture round (is that supposed to sound cooler than Series E?). The financing was … Continue reading “Ambit Raises $30M Venture Round, After Pulling Plug on IPO”
ASCO Wrap-Up, Pathway Medical Grinds It Out, Gates Foundation’s New Digs, & More in Seattle-Area Life Sciences News
This week we had news from a couple of Seattle-area life sciences companies who appeared at a big cancer drug conference, a notable financing story, and a couple of in-depth profiles. —Kirkland, WA-based Pathway Medical Technologies, the maker of a tiny drill that clears out blockages in leg arteries, provided me with a detailed update … Continue reading “ASCO Wrap-Up, Pathway Medical Grinds It Out, Gates Foundation’s New Digs, & More in Seattle-Area Life Sciences News”
Pathway Medical Grinds It Out, Seeks Profit Formula, Three Years After FDA Approval
Selling expensive new medical equipment to doctors today, no matter how good it may be, is no easy thing. Just ask Pathway Medical Technologies. Almost three years have passed since the Kirkland, WA-based company won FDA approval for its first device, which drills through and sucks out tough-to-treat blockages in leg arteries. The company, founded … Continue reading “Pathway Medical Grinds It Out, Seeks Profit Formula, Three Years After FDA Approval”
ASCO Wrap-Up: The Skinny on Cancer News From All Corners of the U.S.
Whoever came up with the phrase “drinking from the fire hose,” could have easily been thinking of the American Society of Clinical Oncology annual meeting. The information on cancer R&D has been flowing furiously the past few days at ASCO, which draws about 30,000 cancer doctors, drug company executives, investors, and journalists. I didn’t attend … Continue reading “ASCO Wrap-Up: The Skinny on Cancer News From All Corners of the U.S.”
Cyterix Raises $9.2M for Cancer Drugs
San Francisco-based Cyterix Pharmaceuticals said today it has raised $9.2 million in a Series A financing from The Column Group and SV Life Sciences. The company, founded in April 2010, is developing drugs that are selectively activated by enzymes known as cytochrome P450s outside the liver—which are thought to reside in tumors, but not healthy … Continue reading “Cyterix Raises $9.2M for Cancer Drugs”
PATH Partners With GSK on Malaria Vaccine
PATH, the Seattle-based global health nonprofit, said it has formed a collaboration with Netherlands-based Crucell and London-based GlaxoSmithKline to develop a next-generation malaria vaccine. The effort will bring together two vaccine approaches in an attempt to improve upon Glaxo’s RTS,S, a vaccine that has shown an ability to protect about half of people who get … Continue reading “PATH Partners With GSK on Malaria Vaccine”
Exelixis Zeroes in on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients
Exelixis gambled a little more than a year ago, deciding to go “all-in” on its lead drug candidate for cancer after many investors lost interest in its strategy of building a broad pipeline with lots of different drugs. It was risky thing to do in a business where most drugs fail in clinical trials, but … Continue reading “Exelixis Zeroes in on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients”
ACT Biotech, Scooping Up Bayer’s Cast-Off, Shows Promise With Stomach Cancer Drug
You know saying about one man’s loss being another man’s gain? That looks like the storyline that’s playing out at San Francisco-based ACT Biotech, which presented some promising results over the weekend with a new cancer drug it picked up off the scrap heap a few years ago from Germany-based Bayer (NYSE: [[ticker:BAY]]). ACT Biotech, … Continue reading “ACT Biotech, Scooping Up Bayer’s Cast-Off, Shows Promise With Stomach Cancer Drug”
Adaptive TCR, a Fred Hutch Spinoff, Snags $5.8M to Take Immune System Profiling Up a Notch
Seattle-based Adaptive TCR, a startup that grew out of immune-system profiling work at the Fred Hutchinson Cancer Research Center, has raised $5.8 million in an equity investment round that could be worth as much as $7.5 million over time. Adaptive TCR, profiled in these pages back in December, has secured the new financing from a … Continue reading “Adaptive TCR, a Fred Hutch Spinoff, Snags $5.8M to Take Immune System Profiling Up a Notch”
The Quest For Biotech Independence: Maybe It Isn’t So Quixotic After All
Conventional wisdom a couple years ago said that the era of the independent biotech giant was over. Nobody would ever again build a multi-billion dollar, fully integrated independent biopharma company on the scale of an Amgen (NASDAQ: [[ticker:AMGN]]), or even a Gilead Sciences (NASDAQ: [[ticker:GILD]]). Drug development is too risky, time-consuming, and expensive. Investors, tired … Continue reading “The Quest For Biotech Independence: Maybe It Isn’t So Quixotic After All”
Gates Foundation Shows Off New Campus to Local Bigwigs: The Photo Gallery
Bill Gates reportedly spent a fair chunk of change, $500 million, on a new campus near the Seattle Center for his charitable foundation. So naturally, it was only a matter of time before the software mogul-turned-humanitarian and his wife Melinda decided to invite about 1,000 or so community leaders in media, politics, and business to … Continue reading “Gates Foundation Shows Off New Campus to Local Bigwigs: The Photo Gallery”
Orexigen, Facing High Hurdle at FDA, Puts Obesity Drug Development on Hold; Shares Tank
San Diego-based Orexigen Therapeutics has been smacked down hard by the FDA, and now the company has decided it’s time to throw up its hands and find something else to do. Orexigen (NASDAQ: [[ticker:OREX]]) said today it is putting on hold any further development of its obesity drug programs after getting what you’d have to … Continue reading “Orexigen, Facing High Hurdle at FDA, Puts Obesity Drug Development on Hold; Shares Tank”
Anthera Raises $47M
Hayward, CA-based Anthera Pharmaceuticals (NASDAQ: [[ticker:ANTH]]) said today it raised $47 million through a stock offering, after deducting expenses. The company sold about 6.7 million shares of stock at $7.50 apiece, and granted its underwriters a 30-day option to buy another 1 million shares. Citi, Leerink Swann, and Canaccord Genuity managed the offering.
Theravance, Glaxo Lung Drug Passes Two Pivotal Trials; Two More to Go
GlaxoSmithKline is counting on a new respiratory drug it is developing with South San Francisco-based Theravance, and today the companies got some good news about the treatment. Glaxo and Theravance (NASDAQ: [[ticker:THRX]]) said today that its once-daily inhaled corticosteroid combined with a long-acting beta agonist (Relovair) passed a pair of pivotal stage studies looking at … Continue reading “Theravance, Glaxo Lung Drug Passes Two Pivotal Trials; Two More to Go”
AVI Biopharma CEO Chris Garabedian Seeks to Avoid Quick Flip, Build Enduring Drug Company
Chris Garabedian took his first shot at being a CEO last December. Immediately, people thought this was a little bit crazy. Friends wondered, why leave a job as an up-and-coming VP of corporate strategy at a biotech powerhouse like Summit, NJ-based Celgene (NASDAQ: [[ticker:CELG]]) to run an obscure little company like AVI Biopharma (NASDAQ: [[ticker:AVII]])? … Continue reading “AVI Biopharma CEO Chris Garabedian Seeks to Avoid Quick Flip, Build Enduring Drug Company”
Infinity Dares to Think Big Against Pancreatic Cancer, Prepares to Show Early Results This Weekend
Infinity Pharmaceuticals’ top execs sometimes get strange looks when they say they are developing a new drug for pancreatic cancer. This, after all, is a wicked malignancy that usually kills patients in just a few months, and has dashed the hopes of many cancer drug developers over the years. Yet Cambridge, MA-based Infinity (NASDAQ: [[ticker:INFI]]) … Continue reading “Infinity Dares to Think Big Against Pancreatic Cancer, Prepares to Show Early Results This Weekend”
Ariad Eagerly Awaits the Big Show, ASCO, To Display Cancer Trial Results
Ariad Pharmaceuticals’ stock has surged 73 percent since New Year’s Day, so you could say CEO Harvey Berger is having a better-than-average year. The Cambridge, MA-based cancer drug developer has seen its market valuation eclipse $1 billion, on a wave of anticipation heading into what could be the most important medical meeting in his company’s … Continue reading “Ariad Eagerly Awaits the Big Show, ASCO, To Display Cancer Trial Results”
Complete Genomics Adds $69M
Complete Genomics (NASDAQ: [[ticker:GNOM]]), the Mountain View, CA-based company that sequences entire human genomes for researchers, has raised about $69 million in a new stock offering. The company sold 5.5 million shares at $12.50 apiece, a 6 percent discount to the closing market price the day before the deal was announced. The offering got a … Continue reading “Complete Genomics Adds $69M”
Optimer Wins FDA Approval of New Antibiotic for Hospital Infections
Turns out that Optimer Pharmaceuticals won’t have to spend the holiday weekend on pins and needles. The San Diego-based biotech company got its wish today, as the FDA approved Optimer’s first new product for sale in the U.S. The FDA cleared fidaxomicin (Dificid) as a new treatment for C. difficile, a hardy bacterial infection that … Continue reading “Optimer Wins FDA Approval of New Antibiotic for Hospital Infections”
Solazyme Finds Investor Appetite for Renewables, Sees Shares Boom on Day One
Solazyme must be getting ready for a heck of a company party this Memorial Day weekend. The renewable oils company pulled off its long-awaited IPO last night, and got a quite bullish (although not exactly LinkedIn-style) reaction from investors. South San Francisco-based Solazyme (NASDAQ: [[ticker:SZYM]]) raised more than $197 million through its initial public offering … Continue reading “Solazyme Finds Investor Appetite for Renewables, Sees Shares Boom on Day One”
Optimer Cruises Into Memorable Memorial Day Weekend, Awaiting FDA Word on Antibiotic
At least a few people in San Diego are sitting tight today at work, unable to get a jump on the holiday weekend. That’s the case at San Diego-based Optimer Pharmaceuticals (NASDAQ: [[ticker:OPTR]]), which is awaiting word from the FDA on whether its first drug can be cleared for sale in the U.S. The agency’s … Continue reading “Optimer Cruises Into Memorable Memorial Day Weekend, Awaiting FDA Word on Antibiotic”
InSite, Merck Sue Sandoz Over Patent
InSite Vision, the Alameda, CA-based developer of drugs for eye diseases, said today it has joined pharma giant Merck in bringing a patent infringement lawsuit against Sandoz, a generic drugmaker. Sandoz has recently filed an abbreviated new drug application with the FDA for clearance to start marketing a generic version of azithromycin (Azacite) for the … Continue reading “InSite, Merck Sue Sandoz Over Patent”
Rigel Pockets $130M in Financing, Seeks To Pick up Pfizer’s Ball and Run With it
New York-based Pfizer (NYSE: [[ticker:PFE]]) is the biggest drug company in the world, so when it slashes costs and dumps drug candidates left and right, people take note. But sometimes what gets overlooked is that one company’s loss is another’s gain, and that’s what appears to be happening at South San Francisco-based Rigel Pharmaceuticals. Rigel … Continue reading “Rigel Pockets $130M in Financing, Seeks To Pick up Pfizer’s Ball and Run With it”
Accelerator’s New Cancer Startup, 23andMe Hanging at the ISB, How to Make $ With No IPO, & More in Seattle-Area Life Sciences News
This week’s biotech news roundup is short and sweet. —Accelerator, the Seattle-based hothouse for biotech startups, is humming with the activity of a new cancer drug startup called Oncofactor. This company is setting out to spur the immune system to fight tumors. —23andMe, the Mountain View, CA-based consumer genetic testing company, made an appearance at … Continue reading “Accelerator’s New Cancer Startup, 23andMe Hanging at the ISB, How to Make $ With No IPO, & More in Seattle-Area Life Sciences News”
Improving Health While Lowering Cost: Come Hear About the Grand Challenge of Healthtech at XSITE on June 16
Most days, I report and write about traditional things people would consider healthcare innovations with big business potential—new drugs, devices, and diagnostics. Most of these things end up adding costs to the healthcare system. But given the ever-rising costs of healthcare in the U.S., more and more entrepreneurial energy is being channeled in other ways … Continue reading “Improving Health While Lowering Cost: Come Hear About the Grand Challenge of Healthtech at XSITE on June 16”
Proteostasis Nabs Partnership, $20M Investment, from Elan To Pursue Neurology Drugs
Cambridge, MA-based Proteostasis Therapeutics has found a big new benefactor to support its R&D against neurological diseases. Proteostasis said today it has formed a strategic alliance with Ireland-based Elan to develop traditional small molecule drugs and diagnostics with Proteostasis against neurodegenerative diseases like Parkinson’s, Huntington’s, and multiple sclerosis. Elan, the developer of the hit multiple … Continue reading “Proteostasis Nabs Partnership, $20M Investment, from Elan To Pursue Neurology Drugs”
23andMe Brings Down the Price of Consumer Genetic Tests, Builds Up Relations With Big Pharma
23andMe is used to lots of eye-rolling from scientists. One geneticist, quoted a year ago in the New York Times, ridiculed the Mountain View, CA-based maker of consumer genetic tests for providing little more than “a really wonderful form of recreation.” One year later, 23andMe CEO Anne Wojcicki stood in front of a room of … Continue reading “23andMe Brings Down the Price of Consumer Genetic Tests, Builds Up Relations With Big Pharma”
Accelerator’s New Startup, Oncofactor, Seeks to Spark Immune System Fight Against Cancer
Seattleites know better than most that the notion that you can spur the immune system to fight cancer is going through a renaissance. So it shouldn’t be any surprise that Accelerator’s newest startup, Oncofactor, is testing out a variation on this red-hot theme. Accelerator, the Seattle-based haven for biotech startups, has plunked down the first … Continue reading “Accelerator’s New Startup, Oncofactor, Seeks to Spark Immune System Fight Against Cancer”
Vertex, On Deadline, Wins FDA Approval for Hepatitis C Drug
[Update: 12:03 pm ET, with pricing info] Vertex’s big day has arrived. The Cambridge, MA-based biotech company has gotten clearance from the FDA to start marketing telaprevir (Incivek) as a new treatment for patients in the U.S. with hepatitis C. The new drug, a protease inhibitor designed to fight the liver-damaging virus, is now approved … Continue reading “Vertex, On Deadline, Wins FDA Approval for Hepatitis C Drug”
Bluebird Bio Looks to Move Past Hot Papers, Charge Ahead in Clinic With Gene Therapy
[Correction: 10:22 am 5/24/11] Bluebird Bio is one of those fortunate companies that can say the top peer-reviewed journals in biomedical research—Science and Nature—have run articles featuring its two lead drug candidates while they are still at the earliest phase of development. CEO Nick Leschly doesn’t want to sound ungrateful—the buzz doesn’t hurt—but he seems … Continue reading “Bluebird Bio Looks to Move Past Hot Papers, Charge Ahead in Clinic With Gene Therapy”
Sangamo Shows Early Promise Against HIV, Hemophilia at Gene Therapy Revival Meeting
Word on the street in Seattle last week was that Big Pharma was sniffing around quite a bit at the American Society of Gene & Cell Therapy annual meeting being held downtown. There was a lot more optimism at this confab than in years past, and Richmond, CA-based Sangamo Biosciences was one of the companies … Continue reading “Sangamo Shows Early Promise Against HIV, Hemophilia at Gene Therapy Revival Meeting”
How to Make Money in Biotech With No Hope of Going Public, Slim Odds of Getting Acquired
Most biotech entrepreneurs I’ve met have a dream that ends one of two ways. They will either take their company public, or sell their startup to a giant drugmaker. Those are the paths to making money, making venture investors happy, and getting the resources needed to take a new drug all the way to the … Continue reading “How to Make Money in Biotech With No Hope of Going Public, Slim Odds of Getting Acquired”
Biogen Gets EU Panel OK for MS Drug
Weston, MA-based Biogen Idec (NASDAQ: [[ticker:BIIB]]) said today that it has received a positive opinion from a committee of the European Medicines Agency, which should pave the way to begin sales in Europe of fampridine (Fampyra) as a new treatment for multiple sclerosis. Based on the committee recommendation, Biogen Idec said it expects to be … Continue reading “Biogen Gets EU Panel OK for MS Drug”
ImmunoGen Grabs $84M
Waltham, MA-based ImmunoGen (NASDAQ: [[ticker:IMGN]]), the developer of targeted antibody drugs for cancer, said today it has raised $84 million through a stock offering. The company sold 7 million new shares at $12 apiece. Jefferies & Co., Oppenheimer & Co., RBC Capital Markets, William Blair & Co., Canaccord Genuity and Morgan Joseph TriArtisan managed the … Continue reading “ImmunoGen Grabs $84M”
See You Tonight at “Separating Hype from Reality in Alternative Fuels”
Gas is $4 a gallon, consumers are steaming, the oil companies keep getting tax breaks, and alternative fuels are still a long way from reaching the consumer masses. What’s going on here? There’s a lot of meaty material to discuss as I’m getting ready for tonight’s Xconomy event, titled “Separating Hype from Reality in Alternative … Continue reading “See You Tonight at “Separating Hype from Reality in Alternative Fuels””
Jennerex Shows Survival Edge for Liver Cancer Patients in Small Study of Anti-Tumor Virus
San Francisco-based Jennerex Biotherapeutics isn’t ready to show results from its tumor-fighting virus at the meeting that attracts all the big boys and girls in the cancer drug business, but today it is unveiling some provocative results that suggest it may help liver cancer patients live longer. Jennerex’s data is still preliminary, and comes from … Continue reading “Jennerex Shows Survival Edge for Liver Cancer Patients in Small Study of Anti-Tumor Virus”
Resolve Maps Out New Biotech Model, SeaGen Expands, Schadt Heads East, & More in Seattle-Area Life Sciences News
Local biotech people and companies were moving onward and upward this week. —Eric Schadt, the shorts-wearing, motorcycle-riding genomics brainiac, the guy who made his name at Seattle’s Rosetta Inpharmatics, is moving to the Big Apple to run a big new genomics institute at Mt. Sinai School of Medicine. Schadt, a co-founder of Seattle-based Sage Bionetworks, … Continue reading “Resolve Maps Out New Biotech Model, SeaGen Expands, Schadt Heads East, & More in Seattle-Area Life Sciences News”
Genentech Gears Up for ASCO, Pushing Data on Personalized Cancer Medicine
It’s the season for playoff-level intensity for a bunch of Big Pharma and biotech companies. They’re all psyched up, over the next two weeks, to show clinical trial results for their drugs at the annual extravaganza for cancer doctors, put on by the American Society of Clinical Oncology (ASCO). Win over those influential doctors, and … Continue reading “Genentech Gears Up for ASCO, Pushing Data on Personalized Cancer Medicine”
Boeing’s NW Biofuel Strategy, Kleiner Perkins’ Natural Gas Startup & More on Deck for Tomorrow’s Alternative Fuels Event
Gas is selling for more than $4 a gallon, and consumers are hopping mad. Even though we’ve all seen this movie before, nobody has yet made a serious impact with alternatives that power motor vehicles with something other than fossil fuels. Finding various clean, renewable, and cost-competitive sources of energy is one of the big … Continue reading “Boeing’s NW Biofuel Strategy, Kleiner Perkins’ Natural Gas Startup & More on Deck for Tomorrow’s Alternative Fuels Event”
Celldex Raises $31.5M, Stock Drops
Needham, MA-based Celldex Therapeutics (NASDAQ: [[ticker:CLDX]]) said today it has raised $31.5 million through a stock offering. The company sold 10 million shares at $3.15 apiece, roughly a 19 percent discount to yesterday’s closing stock price of $3.88, before the deal was announced. Jefferies & Co, Wedbush Securities, Brean Murray, Carret & Co. and Roth … Continue reading “Celldex Raises $31.5M, Stock Drops”
Should Biology Go Open Source? Join the Debate June 16 With Phil Sharp and Stephen Friend
Biology has long been based on a model in which scientists think up a dynamite experiment, gather data, keep it all close to the vest, and publish the (hoped-for) blockbuster results in a top peer-reviewed journal. Like many biologists, MIT’s Phil Sharp made his name following this time-honored method for discovering and disseminating knowledge. Now … Continue reading “Should Biology Go Open Source? Join the Debate June 16 With Phil Sharp and Stephen Friend”
Amyris Sees Reward in Putting One Foot in Front of the Other in Biofuels
The renewable fuels business has been long on talk and short on action for a few years now. That helps explain how Emeryville, CA-based Amyris could achieve impressive financial results simply by fulfilling its promises—even if that means hitting some fairly incremental goals. The company has seen its stock climb 72 percent, from $16 to … Continue reading “Amyris Sees Reward in Putting One Foot in Front of the Other in Biofuels”
PATH VP Takes CEO Gig at Global Impact
Scott Jackson, the vice president of external relations at Seattle-based PATH, is leaving to become the CEO of Global Impact, an Alexandria, VA-based humanitarian organization. Jackson, who oversaw PATH’s advocacy, visibility and fundraising efforts the past five years, will now oversee an organization that has raised more than $1.3 billion for 58 U.S.-based charities, according … Continue reading “PATH VP Takes CEO Gig at Global Impact”
Merck, Genentech Team Up on Hepatitis C Drugs, Raising Ante in Vertex Rivalry
Merck isn’t messing around with its new hepatitis C drug. It has now enlisted a powerhouse partner in its bid to fight for market share against Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]). The Whitehouse Station, NJ-based pharma giant (NYSE: [[ticker:MRK]]) said today that it has formed a non-exclusive alliance with Roche’s Genentech unit to help … Continue reading “Merck, Genentech Team Up on Hepatitis C Drugs, Raising Ante in Vertex Rivalry”
Resolve Nabs $2M For Lupus Drug, First Step on the Road to Returns With No IPO, No M&A
Seattle-based Resolve Therapeutics raised its first $2 million to execute on a plan that challenges about 30 years of conventional wisdom of how you make money in biotech. And it took some creative thinking from a couple of New York-based venture firms to pull it together. The plan, crafted by Resolve CEO Jim Posada, is … Continue reading “Resolve Nabs $2M For Lupus Drug, First Step on the Road to Returns With No IPO, No M&A”
Marina Biotech Adds $6.9M
Bothell, WA-based Marina Biotech (NASDAQ: [[ticker:MRNA]]), the developer of RNA interference treatments, said today it has raised gross proceeds of $6.9 million through a stock offering. The company sold 22.3 million securities units, made up of one share of common stock and one warrant to buy a share of common stock. Marina has said it … Continue reading “Marina Biotech Adds $6.9M”
Bill Gates’ Favorite Biofuel Company on the Docket for Thursday’s Alternative Fuels Event
There might be 100 good energy ideas in the U.S. today, as Bill Gates said last week at a fundraiser for Climate Solutions, but one of the really big ones he’s backing is San Diego-based Sapphire Energy. This company, which has raised more than $300 million to execute on its vision of making algae a … Continue reading “Bill Gates’ Favorite Biofuel Company on the Docket for Thursday’s Alternative Fuels Event”
Amylin Sues Eli Lilly, Arguing Breach of Contract in Marketing Rival Diabetes Drug
[Updated: 8:55 am PT] Amylin Pharmaceuticals is hauling one of its big partners, Eli Lilly, into court. San Diego-based Amylin (NASDAQ: [[ticker:AMLN]]) said today it has filed a suit in the U.S. District Court for Southern California, that accuses Lilly of anticompetitive behavior and violating a 2002 agreement between the companies that covers the marketing … Continue reading “Amylin Sues Eli Lilly, Arguing Breach of Contract in Marketing Rival Diabetes Drug”